Literature DB >> 9637795

A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database.

T M Hernandez-Boussard1, P Hainaut.   

Abstract

Mutations in the p53 gene are common in lung cancer. Using data from the the International Agency for Research on Cancer p53 mutation database (R1), we have analyzed the distribution and nature of p53 mutations in 876 lung tumors described in the literature. These analyses confirm that G to T transitions are the predominant type of p53 mutation in lung cancer from smokers. The most frequently mutated codons include 157, 158, 179, 248, 249, and 273, and several of them (157, 248, and 273) have been shown to correspond to sites of in vitro DNA adduct formation by metabolites of polycyclic aromatic hydrocarbons (PAHs) such as benzo(a)pyrene. Furthermore, most of the base changes at codons 248, 249, and 273 in lung cancer differ from those commonly observed at these codons in other cancers reported in the database. Thus, lung cancer from smokers shows a distinct, unique p53 mutation spectrum that is not observed in lung cancer from nonsmokers. These results further strengthen the association between active smoking, exposure to PAHs, and lung cancer. They also indicate that a different pattern of mutations occurs in nonsmokers, and this observation may help to identify other agents causally involved in lung cancer in nonsmokers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637795      PMCID: PMC1533115          DOI: 10.1289/ehp.98106385

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  45 in total

Review 1.  Mutational spectra: from model systems to cancer-related genes.

Authors:  E Dogliotti
Journal:  Carcinogenesis       Date:  1996-10       Impact factor: 4.944

2.  p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels.

Authors:  E H Kure; D Ryberg; A Hewer; D H Phillips; V Skaug; R Baera; A Haugen
Journal:  Carcinogenesis       Date:  1996-10       Impact factor: 4.944

3.  Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers.

Authors:  M F Denissenko; A Pao; G P Pfeifer; M Tang
Journal:  Oncogene       Date:  1998-03-12       Impact factor: 9.867

4.  Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53.

Authors:  M F Denissenko; A Pao; M Tang; G P Pfeifer
Journal:  Science       Date:  1996-10-18       Impact factor: 47.728

5.  Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression.

Authors:  D G Guinee; W D Travis; G E Trivers; V M De Benedetti; H Cawley; J A Welsh; W P Bennett; J Jett; T V Colby; H Tazelaar
Journal:  Carcinogenesis       Date:  1995-05       Impact factor: 4.944

6.  A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients.

Authors:  K Kondo; H Tsuzuki; M Sasa; M Sumitomo; T Uyama; Y Monden
Journal:  J Surg Oncol       Date:  1996-01       Impact factor: 3.454

7.  Mutation spectrum of cigarette smoke condensate in Salmonella: comparison to mutations in smoking-associated tumors.

Authors:  D M DeMarini; M L Shelton; J G Levine
Journal:  Carcinogenesis       Date:  1995-10       Impact factor: 4.944

Review 8.  p53 and ras gene mutations in lung cancer: implications for smoking and occupational exposures.

Authors:  K Husgafvel-Pursiainen; M Ridanpää; S Anttila; H Vainio
Journal:  J Occup Environ Med       Date:  1995-01       Impact factor: 2.162

Review 9.  The role of individual susceptibility in cancer burden related to environmental exposure.

Authors:  H Bartsch; E Hietanen
Journal:  Environ Health Perspect       Date:  1996-05       Impact factor: 9.031

10.  Cigarette smoking and p53 mutations in lung cancer and bladder cancer.

Authors:  K Husgafvel-Pursiainen; A Kannio
Journal:  Environ Health Perspect       Date:  1996-05       Impact factor: 9.031

View more
  19 in total

1.  Large cell lung carcinoma with unusual imaging feature, immunophenotype and genetic finding.

Authors:  Jelena Stojsic; Ruza Stevic; Milica Kontic; Zorica Stojsic; Neda Drndarevic; Vera Bunjevacki; Biljana Jekic
Journal:  Pathol Oncol Res       Date:  2010-04-21       Impact factor: 3.201

Review 2.  DNA adducts: Formation, biological effects, and new biospecimens for mass spectrometric measurements in humans.

Authors:  Byeong Hwa Yun; Jingshu Guo; Medjda Bellamri; Robert J Turesky
Journal:  Mass Spectrom Rev       Date:  2018-06-11       Impact factor: 10.946

3.  Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice.

Authors:  Ralf Ruediger; Jennifer Ruiz; Gernot Walter
Journal:  Mol Cell Biol       Date:  2011-07-26       Impact factor: 4.272

4.  Kras, Egfr, and Tp53 Mutations in B6C3F1/N Mouse and F344/NTac Rat Alveolar/Bronchiolar Carcinomas Resulting from Chronic Inhalation Exposure to Cobalt Metal.

Authors:  Hue-Hua L Hong; Mark J Hoenerhoff; Thai-Vu Ton; Ronald A Herbert; Grace E Kissling; Michelle J Hooth; Mamta Behl; Kristine L Witt; Stephanie L Smith-Roe; Robert C Sills; Arun R Pandiri
Journal:  Toxicol Pathol       Date:  2015-06-09       Impact factor: 1.902

5.  Human lung cancer and p53: the interplay between mutagenesis and selection.

Authors:  S N Rodin; A S Rodin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

Review 6.  Molecular epidemiology to better predict lung cancer risk.

Authors:  Mary E Reid; Regina Santella; Christine B Ambrosone
Journal:  Clin Lung Cancer       Date:  2008-05       Impact factor: 4.785

Review 7.  Clinical implication of p53 mutation in lung cancer.

Authors:  Barbara G Campling; Wafik S El-Deiry
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

Review 8.  Lung cancer in never smokers: molecular profiles and therapeutic implications.

Authors:  Charles M Rudin; Erika Avila-Tang; Curtis C Harris; James G Herman; Fred R Hirsch; William Pao; Ann G Schwartz; Kirsi H Vahakangas; Jonathan M Samet
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

9.  2020 Innovation-Based Optimism for Lung Cancer Outcomes.

Authors:  Erin L Schenk; Tejas Patil; Jose Pacheco; Paul A Bunn
Journal:  Oncologist       Date:  2020-12-20

Review 10.  Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns.

Authors:  I A Lea; M A Jackson; X Li; S Bailey; S D Peddada; J K Dunnick
Journal:  Carcinogenesis       Date:  2007-08-11       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.